Peter Lu, MD
Endocrinology, Diabetes & Metabolism · Lawrenceville, GANPI 1891883104
Payments from drug & device makers
Across 166 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Amgen$359
- Novo Nordisk$327
- Dexcom, Inc.$321
- Insulet Corporation$256
- Tandem Diabetes Care, Inc.$145
- plus $869 from 20 others
What the payments were for
- Food & beverage$3,713100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 49 | $1,436 |
| Amgen(2 entities) | 18 | $359 |
| Novo Nordisk | 21 | $327 |
| Dexcom, Inc. | 15 | $321 |
| Insulet Corporation | 23 | $256 |
| Tandem Diabetes Care, Inc. | 1 | $145 |
| Medtronic(2 entities) | 9 | $130 |
| Novartis | 2 | $127 |
| AstraZeneca | 2 | $116 |
| BETA Bionics, Inc. | 2 | $112 |
| Boehringer Ingelheim | 3 | $57 |
| Amneal Pharmaceuticals LLC | 3 | $50 |
| Ferring Pharmaceuticals Inc. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Senseonics, Incorporated | 1 | $23 |
| AbbVie | 2 | $23 |
| Johnson & Johnson | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Roche Diabetes Care, Inc. | 1 | $14 |
| Silk Road Medical, Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
| Recordati_rare_diseases_inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$608
- t-slim insulin pump$145
- FARXIGA$104
- AIMOVIG$100
- KESIMPTA$100
How this compares
$3,713 in reported general payments places this provider in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 209 | $330,311 |
| JardianceEmpagliflozin | 119 | $179,903 |
| MounjaroTirzepatide | 85 | $130,650 |
| ForteoTeriparatide | 26 | $122,014 |
| TrulicityDulaglutide | 56 | $108,048 |
| JanuviaSitagliptin Phosphate | 65 | $92,069 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $78,738 |
| FarxigaDapagliflozin Propanediol | 55 | $64,760 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $46,714 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $32,213 |
| Gvoke Hypopen 2-PackGlucagon | 48 | $31,966 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $29,063 |
| Novolog FlexpenInsulin Aspart | 65 | $29,005 |
| RybelsusSemaglutide | 13 | $25,143 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $25,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog | $17 | $366,070179 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $327 | $362,194240 claims |
| Boehringer IngelheimJardiance | $57 | $179,903119 claims |
| AstraZenecaFarxiga | $116 | $64,76055 claims |
| AbbVieSynthroid | $23 | $18,124200 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $50 | $4,842673 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Lawrenceville
- Adeniyi OdugbesanLawrenceville$1.8M
- David ShoreLawrenceville$83K
- David ArkinLawrenceville$15K
- Aparna MahakalaLawrenceville$12K
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.